
Returning to lead the Global Fund, Mark Dybul argues that the future of global health lies with domestic health systems, not agency mergers in Geneva. Evoking the founding ambition of the early 2000s, the incoming executive director explains how the Accra Reset and US bilateral aid can align under unified national plans – and how his active ties to Washington can help navigate political fragmentation.
Health Policy Watch: You’re stepping back into the Global Fund at a critical moment for multilateral health. What’s different about this term compared to your first stint starting in 2013?
Mark Dybul: The Fund is in a remarkably strong position – I would say the strongest position it’s ever been in. Peter [Sands] deserves a lot of praise and credit for leading the Fund over the last nine years with the full partnership of the board and the secretariat, built on the depth and breadth of cross-sector partnership that is central to the next phase of global health.

What’s really different is the landscape. It has changed radically from the last time I was executive director. I’ve been part of that shifting landscape for the last nine years from my position at Georgetown [University], working closely with countries and communities as they’ve already begun to prepare for transitions. This is not new; it’s happening in an accelerated way, but it’s been moving.
It reminds me a little bit of 2000, but in a totally different way. In 2000, there was enormous energy, excitement, lots of new resources, lots of new institutions.
Today is more about asking: “Where are we, and where are countries today?” This is something I don’t think gets enough emphasis: countries are in a completely different position than they were 25 years ago. Their technical capacity, their desire for ownership and sovereignty within a supportive international system of solidarity, and their financial capacity, have been transformed. GDPs in countries have grown from single-digit billions to triple-digit billions, some growing to trillions. While external financing is also facing a very different climate, that shift reflects the progress countries have made.
HPW: You’ve argued that global health aid must end dependencies and shift toward national sovereignty – a core pillar of the Accra Reset, which calls for a five- to 10-year wind-down of duplicative functions. What does that transition look like for the Global Fund under your leadership?
Dybul: That will ultimately be determined by the board within the international architecture, but people are jumping straight to that one piece of the Accra Reset. The other components are actually pivotal to making that happen. Those other pieces are supporting countries for successful transitions – not just from external financing, but to a new approach that some countries are in a position to adopt.
That includes a reduction in external financing, which they want, but it’s going to take time; it has to be careful, and it has to be flexible and responsive because countries will go in different directions. There are some countries that will take much longer, some that are in a crisis state, and some that could enter a crisis state, so there’s no one pathway here.
I think the most critical parts are successful, well-planned, and executed transitions where possible, which frees up capital for countries that will take longer. 60% to 80% of current bilateral and multilateral budgets go to countries that are in a very strong position to be able to transition over time, which is something they very much want to do.
On the architecture piece: I used to spend a lot more time on this. Right now, to me, the focus – and again, this is what the Accra Reset says – is on the countries and the communities to best support them to achieve better health outcomes over the coming years, while they decrease external financing requirements because of their capacity to increase domestic financing.
If we take that perspective, then what countries want and need from the international system will begin to emerge. That’s why in the Accra Reset it says five to 10 years, because we don’t know yet what that looks like, and it will evolve – and I won’t be executive director when that happens.
Country impact over Geneva-centered consolidation

HPW: On that outcome perspective – in malaria, TB, and looking ahead to the HIV pipeline – there is an increasing convergence of vaccine and therapeutic options. Should Gavi and the Global Fund work closer together or even merge?
Dybul: I’ve always believed that Gavi and the Global Fund should work more closely together. When I was executive director the last time, we did joint trips together, we worked on plans together. It’s been very exciting to see Peter’s leadership with Sania [Nishtar] putting together a task force where they actually work closely together, especially on malaria right now because we have a malaria vaccine and malaria treatment. From what I’ve seen from the outside, there’s been tremendous partnership. All of us coming together to support countries and communities is the path to that transition, and it will lead to a natural architecture change.
I don’t spend a lot of time thinking about mergers and acquisitions, because then the focus is in Geneva, New York, or Copenhagen. The focus needs to be in the country and how we all work together to support them. Again, the Board sets the direction and the vision, and we execute. But there’s tremendous opportunity to work together to support countries in a stronger way.
HPW: The Global Fund leverages massive scale for rock-bottom prices, predominantly from Asia. With Africa CDC pushing for regional manufacturing sovereignty, is the Fund prepared to pay a price premium for African-made diagnostics and therapeutics?
Dybul: That will require extensive board discussions, but price supplements are only one approach. This is something that we started when I was there, and Peter and the secretariat have really built on: how you actually score things in procurement.
For example, initially when I came in, it was only on cost of goods, and not on shipping costs or on-time and full delivery. Once you start building those in, you can actually start tilting towards more regional and local production because those costs were invisible before in costing decisions. In fact, there was a significant shift towards local manufacture of bed nets and things that could be done locally.
At the same time, we have to recall that two of the best antiretroviral producers in the world were in Africa, and both failed because they didn’t have access to markets. These are longer-term conversations that the Board has to lead, but technology and pooled mechanisms give us opportunities that could be a win-win for everyone, especially by improving demand forecasting.
Managing the risks of new tech philanthropy

HPW: Global health is seeing an influx of AI philanthropy, raising alarms over data extraction and private-sector priorities. How will the Global Fund channel this tech wave without compromising national data sovereignty?

Dybul: Sovereignty is not just financing; it’s also data sovereignty, and planning and execution sovereignty. I’ve had the privilege of working with some of these tech groups in my life and have grants from some of them, so I know them and know how they function.
They are deeply committed, very well-intentioned people, and it’ll be a process of working together. Their goal is to get the greatest impact, and that is going to require deep engagement of countries and communities.
By working together and understanding the complexities country by country – because one size does not fit all – I think this can be a tremendous opportunity for the future, especially as public financing is likely to continue to decrease over time.
As you point out, there are risks, and the risks have to be managed. It comes back to something unique about the Global Fund: the strength of the partnership, the fact that foundations and private sector actors are at the table with a voting seat on the Board. I want to emphasise that: the money is not coming directly from the tech companies; they don’t own the data that they put money in for. I worry less about data sovereignty because these are not the tech companies coming in; these are tech companies giving funds through other mechanisms. But there are issues about planning, execution, and flexibility that need to be worked out.
And I really want to keep emphasising: when I say countries, it’s communities too. Governments are hugely important, but so are communities and non-governmental organisations; they deliver enormous amounts of healthcare – in some countries, 40% of healthcare delivery is outside the public sector.
HPW: Speaking of communities – in many transitioning countries, domestic governments are openly hostile to funding harm reduction or LGBTQ+ programmes. If co-financing takes over and drops key populations, will the Global Fund continue directly financing civil society outside government channels?
Dybul: These are board decisions, not secretariat decisions. Having said that, this is not the first time we’ve faced this. When I was executive director before, we worked with UNAIDS in Latin America to help governments understand that non-governmental entities and communities are integral to their health systems.
We ran numbers showing finance ministries that an uncontrolled epidemic among key populations would destroy their national budgets and fiscal sovereignty. In response, several countries actually changed laws so governments could legally transfer state funding to civil society groups delivering these frontline services. It is a risk, and we have to pay very careful attention to it.
There are other potential funding sources – philanthropies that are now focusing on this. I’ve spent a fair amount of time over the last five years working with philanthropies to understand this risk, and that these populations have to be involved and protected, or you will not control your epidemics, which is the core goal of the Global Fund. It’s a complex dynamic, but it’s something that’s very front and centre in my mind, and I know it’s front and centre in the board’s mind and across delegations.
Aligning US bilateralism with country sovereignty

HPW: Despite your strong bipartisan ties in Washington, the current political climate favours bilateral deals over multilateral pooling. How do you satisfy Washington’s demands without alienating the rest of the Board?
Dybul: It comes back to working collaboratively, humbly, and everyone aligning under national plans. That’s actually what the current people in the [US] State Department are calling for: that we all align under national plans, and that’s what the countries want.
All working together, as long as everyone’s aligned with that national plan, with that national budget, with the reporting requirements – it can be bilateral, it can be multilateral, it can be whatever which way you want. There might be disagreements, but you’ll have to work that out in the country, with the country, which will be radically different from place to place.
I’m very optimistic. I have spent a lot of time in a bipartisan way working with multiple administrations and multiple Congresses, and I’m very active with Congress and the administration right now.
2000 gave this great opportunity because of huge amounts of money; reductions in resources can lead to innovation and a whole new way of doing things, including a new way to involve communities and non-governmental organisations. Think of all the things people said were impossible in 2000, and nearly all of them have been achieved!
As we’re looking forward, rather than saying, “This is going to be so difficult, it’s going to be impossible,” why don’t we start looking as we did then: “Well yeah, true, but what are the opportunities? How do we make it work? And how do we solve problems?” If everyone comes together with a solution-minded approach, these are very solvable problems.
Image Credits: Global Fund/Vincent Becker, HPW/Felix Sassmannshausen, Elements Interactive via Pexels, mk_photoz via Pexels, Georgetown University, Ramaz Bluashvili via Pexels.












































